When cells expire, they leave behind an activity log of sorts: RNA expelled into blood plasma that reveals changes in gene ...

Fetal Focus uses non-invasive prenatal testing to detect key genetic conditions without needing the father’s DNA, keeping ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the ...

When cells expire, they leave behind an activity log of sorts: RNA expelled into blood plasma that reveal changes in gene ...

A randomized controlled trial tested a model using donor-derived cell-free DNA for predicting graft rejection.

Antimicrobial resistance is a lurking threat in hospitals around the world. As more strains of bacteria and other microbes ...

Myriad Genetics posted Q2 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%.

Key Points Revenue (GAAP) jumped 32.2% year over year to $546.6 million in Q2 2025, beating GAAP revenue estimates by 14.8%. Loss per share (GAAP) came in at $(0.74), missing expectations due to legal ...

Investing.com -- Natera, Inc. (NASDAQ: NTRA ), a cell-free DNA and precision medicine company, saw its shares surge 13.4% after reporting second-quarter financial results that significantly exceeded ...

Overview of the MarketThe global Prenatal Genetic Testing Market is valued at USD 7.01 billion in 2024 and is projected to ...